Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$49.94
At close: May 9, 4:00 PM EDT
$49.94
0.000.00%
Pre-Market: May 9, 4:00 PM EDT
Comments
Loading...
Bio-Techne Analyst Ratings and Price Targets | NASDAQ:TECH | Benzinga
Bio-Techne Corp has a consensus price target of $106.79 based on the ratings of 16 analysts. The high is $465 issued by Credit Suisse on August 25, 2022. The low is $60 issued by Stifel on May 8, 2025. The 3 most-recent analyst ratings were released by UBS, RBC Capital, and Benchmark on May 9, 2025, May 8, 2025, and May 8, 2025, respectively. With an average price target of $69.33 between UBS, RBC Capital, and Benchmark, there's an implied 38.83% upside for Bio-Techne Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
RBC Capital
Benchmark
Stifel
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Bio-Techne
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 40.17% | UBS | Dan Leonard55% | $95 → $70 | Maintains | Buy | Get Alert |
| 05/08/2025 | Buy Now | 26.15% | RBC Capital | Conor McNamara36% | $72 → $63 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 50.18% | Benchmark | Robert Wasserman48% | $95 → $75 | Maintains | Buy | Get Alert |
| 05/08/2025 | Buy Now | 20.14% | Stifel | Daniel Arias77% | $75 → $60 | Maintains | Hold | Get Alert |
| 04/09/2025 | Buy Now | — | Keybanc | Paul Knight55% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 03/18/2025 | Buy Now | 50.18% | Evercore ISI Group | Daniel Markowitz11% | → $75 | Initiates | → Outperform | Get Alert |
| 03/04/2025 | Buy Now | 40.17% | Citigroup | Patrick Donnelly80% | $80 → $70 | Maintains | Neutral | Get Alert |
| 02/19/2025 | Buy Now | 36.16% | Baird | Catherine Schulte66% | $88 → $68 | Downgrade | Outperform → Neutral | Get Alert |
| 02/06/2025 | Buy Now | 60.19% | RBC Capital | Conor McNamara36% | $79 → $80 | Maintains | Sector Perform | Get Alert |
| 02/06/2025 | Buy Now | 80.22% | Scotiabank | Sung Ji Nam44% | $88 → $90 | Maintains | Sector Outperform | Get Alert |
| 02/06/2025 | Buy Now | 80.22% | Keybanc | John Vinh71% | $80 → $90 | Maintains | Overweight | Get Alert |
| 10/31/2024 | Buy Now | 76.21% | Scotiabank | Sung Ji Nam44% | $83 → $88 | Maintains | Sector Outperform | Get Alert |
| 10/31/2024 | Buy Now | 68.2% | Baird | Catherine Schulte66% | $82 → $84 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 90.23% | Benchmark | Robert Wasserman48% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 40.17% | RBC Capital | Conor McNamara36% | $72 → $70 | Maintains | Sector Perform | Get Alert |
| 08/08/2024 | Buy Now | 64.2% | Baird | Catherine Schulte66% | $81 → $82 | Maintains | Outperform | Get Alert |
| 05/22/2024 | Buy Now | 70.2% | Citigroup | Patrick Donnelly80% | → $85 | Downgrade | Buy → Neutral | Get Alert |
| 05/02/2024 | Buy Now | 90.23% | Benchmark | Robert Wasserman48% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 62.19% | Baird | Catherine Schulte66% | $73 → $81 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | 64.2% | Deutsche Bank | Justin Bowers47% | $85 → $82 | Maintains | Buy | Get Alert |
| 02/02/2024 | Buy Now | 30.16% | Stifel | Daniel Arias77% | → $65 | Downgrade | Buy → Hold | Get Alert |
| 02/02/2024 | Buy Now | 74.21% | Stephens & Co. | Jacob Johnson58% | $92 → $87 | Maintains | Overweight | Get Alert |
| 02/02/2024 | Buy Now | 50.18% | RBC Capital | Conor McNamara36% | $85 → $75 | Maintains | Sector Perform | Get Alert |
| 12/07/2023 | Buy Now | 60.19% | UBS | Dan Leonard55% | → $80 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | 30.16% | Stifel | Daniel Arias77% | $104 → $65 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 60.19% | Citigroup | Patrick Donnelly80% | $100 → $80 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 66.2% | RBC Capital | Conor McNamara36% | $85 → $83 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | 60.19% | Keybanc | Paul Knight55% | $115 → $80 | Maintains | Overweight | Get Alert |
| 09/12/2023 | Buy Now | 72.21% | RBC Capital | Conor McNamara36% | → $86 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/28/2023 | Buy Now | — | William Blair | Matt Larew18% | — | Initiates | → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 140.29% | Benchmark | Robert Wasserman48% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 100.24% | Stephens & Co. | Jacob Johnson58% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 80.22% | RBC Capital | Conor McNamara36% | $89 → $90 | Maintains | Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | 100.24% | Stephens & Co. | Jacob Johnson58% | → $100 | Reiterates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 100.24% | Baird | Catherine Schulte66% | $99 → $100 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | 76.21% | RBC Capital | Conor McNamara36% | $89 → $88 | Maintains | Sector Perform | Get Alert |
| 02/03/2023 | Buy Now | 140.29% | Benchmark | Robert Wasserman48% | → $120 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 120.26% | SVB Leerink | Puneet Souda57% | $125 → $110 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | 130.28% | Keybanc | Paul Knight55% | $125 → $115 | Maintains | Overweight | Get Alert |
| 01/10/2023 | Buy Now | 80.22% | Wells Fargo | Timothy Daley54% | → $90 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | 100.24% | Deutsche Bank | Justin Bowers47% | → $100 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 100.24% | Citigroup | Patrick Donnelly80% | $81.25 → $100 | Upgrade | Neutral → Buy | Get Alert |
| 12/07/2022 | Buy Now | 78.21% | RBC Capital | Conor McNamara36% | → $89 | Initiates | → Sector Perform | Get Alert |
| 12/05/2022 | Buy Now | 110.25% | Stephens & Co. | Jacob Johnson58% | $420 → $105 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 901.2% | SVB Leerink | Puneet Souda57% | $550 → $500 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 831.12% | Credit Suisse | Dan Leonard55% | → $465 | Initiates | → Outperform | Get Alert |
| 08/16/2022 | Buy Now | 620.87% | Wells Fargo | Timothy Daley54% | $370 → $360 | Maintains | Underweight | Get Alert |
| 08/05/2022 | Buy Now | 861.15% | Stephens & Co. | Jacob Johnson58% | $500 → $480 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Bio-Techne (TECH) stock?
The latest price target for Bio-Techne (NASDAQ:TECH) was reported by UBS on May 9, 2025. The analyst firm set a price target for $70.00 expecting TECH to rise to within 12 months (a possible 40.17% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Techne (TECH)?
The latest analyst rating for Bio-Techne (NASDAQ:TECH) was provided by UBS, and Bio-Techne maintained their buy rating.
When was the last upgrade for Bio-Techne (TECH)?
The last upgrade for Bio-Techne Corp happened on January 10, 2023 when Wells Fargo raised their price target to $90. Wells Fargo previously had an underweight for Bio-Techne Corp.
When was the last downgrade for Bio-Techne (TECH)?
The last downgrade for Bio-Techne Corp happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Bio-Techne Corp.
When is the next analyst rating going to be posted or updated for Bio-Techne (TECH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Techne, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Techne was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Bio-Techne (TECH) correct?
While ratings are subjective and will change, the latest Bio-Techne (TECH) rating was a maintained with a price target of $95.00 to $70.00. The current price Bio-Techne (TECH) is trading at is $49.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
